Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report

Tepotinib, the novel MET-tyrosine kinase inhibitor, shows an antitumor effect for patients with non-small-cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation. In January 2022, the AmoyDx® Pan Lung Cancer polymerase chain reaction Panel (AmoyDx® panel), which had a shorter turnaround tim...

Descripción completa

Detalles Bibliográficos
Autores principales: Makimoto, Go, Shimonishi, Atsushi, Ohashi, Kadoaki, Ninomiya, Kiichiro, Higo, Hisao, Kato, Yuka, Fujii, Masanori, Kubo, Toshio, Ichihara, Eiki, Hotta, Katsuyuki, Tabata, Masahiro, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149432/
https://www.ncbi.nlm.nih.gov/pubmed/35702678
http://dx.doi.org/10.1159/000524326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149432/
https://www.ncbi.nlm.nih.gov/pubmed/35702678
http://dx.doi.org/10.1159/000524326

Ejemplares similares